Cumming John G, Brown Simon J, Cooper Anne E, Faull Alan W, Flynn Anthony P, Grime Ken, Oldfield John, Shaw John S, Shepherd Emma, Tucker Howard, Whittaker David
Respiratory and Inflammation Research Area, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
Bioorg Med Chem Lett. 2006 Jul 1;16(13):3533-6. doi: 10.1016/j.bmcl.2006.03.089. Epub 2006 May 2.
SAR and PK studies led to the identification of N-(1-{(3R)-3-(3,5-difluorophenyl)-3-[4-methanesulfonylphenyl] propyl}piperidin-4-yl)-N-ethyl-2-[4-methanesulfonylphenyl]acetamide as a highly potent and selective ligand for the human CCR5 chemokine receptor with good oral pharmacokinetic properties.
